kabutan

Mochida Pharma, Ordinary Profit Forecast for the Fiscal Year Revised Upward to an Unexpected 36% Increase

Fri Feb 6, 2026 2:00 pm JST Earnings

4534 Mochida Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

Mochida Pharmaceutical Co.,Ltd. <4534> [TSE Prime] announced its financial results in the afternoon session on February 6th (14:00). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) increased 9.2% from the same period last year, reaching 8.34 billion yen.

In addition, the full-year forecast for consolidated ordinary profit has been revised upward 46.7%, from the previous forecast of 7.50 billion yen to 11.0 billion yen (compared to 8.06 billion yen in the previous period), turning to a 36.4% increase in the consolidated ordinary profit outlook.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated ordinary profit for the October to March period (second half) is expected to increase 2.5 times, from the previous forecast of 2.32 billion yen to 5.82 billion yen (compared to 3.98 billion yen in the same period of the previous year), turning to a 46.0% increase in the consolidated ordinary profit outlook.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit decreased to 3.16 billion yen, an 11.1% decrease compared to the same period last year. The operating profit margin significantly dropped from 11.6% in the same period last year to 7.9%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 78,218 5,791 6,059 4,444 123.5 100.4 Feb 5, 2024 J-GAAP
Apr - Dec, 2024 80,731 7,243 7,640 5,605 158.1 94.7 Feb 7, 2025 J-GAAP
Apr - Dec, 2025 87,487 7,526 8,346 6,342 178.9 75.9 Feb 6, 2026 J-GAAP
YoY +8.4% +3.9% +9.2% +13.1% +13.2%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2025 Prev 55,515 2,033 2,321 1,544 43.6 40 Nov 4, 2025 J-GAAP
Oct - Mar, 2025 New 60,515 4,533 5,821 4,544 128.2 40 Feb 6, 2026 J-GAAP
Revision Rate +9.0% +123.0% +150.8% +194.3% +194.3%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 110,500 7,000 7,500 5,400 152.3 80 May 12, 2025 J-GAAP
Mar, 2026 New 115,500 9,500 11,000 8,400 237.0 80 Feb 6, 2026 J-GAAP
Revision Rate +4.5% +35.7% +46.7% +55.6% +55.6%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 54,063 4,333 3,988 2,860 80.7 40 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance 60,515 4,533 5,821 4,544 128.2 40 Feb 6, 2026 J-GAAP
YoY +11.9% +4.6% +46.0% +58.9% +58.9%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 102,885 5,802 6,037 4,547 126.8 80 May 13, 2024 J-GAAP
Mar, 2025 105,159 8,126 8,067 5,685 160.4 80 May 12, 2025 J-GAAP
Mar, 2026 Guidance 115,500 9,500 11,000 8,400 237.0 80 Feb 6, 2026 J-GAAP
YoY +9.8% +16.9% +36.4% +47.8% +47.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 29,635 3,450 3,561 2,780 78.4 11.6 Feb 7, 2025 J-GAAP
Jan - Mar, 2025 24,428 883 427 80 2.3 3.6 May 12, 2025 J-GAAP
Apr - Jun, 2025 26,631 2,572 2,783 1,894 53.4 9.7 Aug 1, 2025 J-GAAP
Jul - Sep, 2025 28,354 2,395 2,396 1,962 55.4 8.4 Nov 4, 2025 J-GAAP
Oct - Dec, 2025 32,502 2,559 3,167 2,486 70.1 7.9 Feb 6, 2026 J-GAAP
YoY +9.7% -25.8% -11.1% -10.6% -10.6%

Related Articles